Shield for the blood: new drug aims to protect patients from harsh chemo side effects
NCT ID NCT07255612
Summary
This study is testing whether a drug called trilaciclib can protect a patient's bone marrow and blood cells during chemotherapy for advanced triple-negative breast cancer. The goal is to reduce severe side effects like infections and fatigue, which often force doctors to delay or reduce chemotherapy doses. The trial will enroll about 29 patients who have already tried at least two other chemotherapy treatments to see if this protective approach helps them better tolerate the cancer therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.